Association between IFN-λ 3 Gene Polymorphisms and Outcome of Treatment with Direct Acting Antivirals in Chronic HCV-Infected Egyptian Patients

References

• Abdo AA, Mohamed Al-Ahdal MN, Khalid SS, Helmy A, Sanai FM, Alswat K, Alhamoudi W, Ali SM, Al-Ashgar HI, Al-Mdani A, et al. 2013. IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection. Hepatol. Int. 7(2):533–38.
   PubMed Web of Science ®Google Scholar
• Aljanabi SM, Martinez I. 1997. Universal and rapid salt-extraction of high quality genomic DNA for PCR-based techniques. Nucleic Acid Res. 25:4692–93.
   PubMed Web of Science ®Google Scholar
• Asnavandi M, Zargar M, Vaziri F, Jamnani FR, Gharibzadeh S, Fateh A, Siadat SD. 2017. EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C. Genes. Immun. 18(3):144–51. doi:10.1038/gene.2017.12. Epub 2017 Jul 13.
   PubMed Web of Science ®Google Scholar
• Bostan N, Mahmood T. 2010. An overview about hepatitis C; a devastating virus. Crit. Rev. Microbiol. 36:91–133.
   PubMed Web of Science ®Google Scholar
• Cholongitas E, Pipili C, Papatheodoridis G. 2015. Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients. World J. Gastroenterol. 21(32):9526–33.
   PubMed Web of Science ®Google Scholar
• Daw MA, Dau AA. 2012. Hepatitis C virus in Arab world: a state of concern. Sci. J. 2012:719494. PMID: 22629189. doi:10.1100/2012/719494.
   Google Scholar
• De Francesco R, Tomei L, Altamura S, Summa V, Migliaccio G. 2003. Approaching a new era for hepatitis C virus therapy: inhibitor of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res. 8:1–16.
   Google Scholar
• Dellgren C, Gad HH, Hamming OJ, Melchjorsen J, Hartmann R. 2009. Human interferon-lambda3 is a potent member of the type III interferon family. Genes. Immun. 10:125–31.
   PubMed Web of Science ®Google Scholar
• El Raziky M, Gamil M, Ashour MK, Sameea EA, Doss W, Hamada Y, Van Dooren G, DeMasi R, Keim S, Lonjon-Domanec I, et al. 2017. Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naïve and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis. J. Viral. Hepat. 24(2):102–10. doi:10.1111/jvh.12625. Epub 2016 Oct 27.
   PubMed Web of Science ®Google Scholar
• El-Awady MK, Bader El Din NG, Tabll A, El Hosary Y, Abdel Aziz AO, El Khayat H, Salama M, Abdel Hafez TH. 2013. IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patients. World J. Gastroentero. 19:290–98.
   PubMed Web of Science ®Google Scholar
• El-Awady MK, Mostafa L, Tabll AA, Abdelhafez TH, Bader El Din NG, Zayed N, Shenawy RE, El Abd Y, Hasan RM, Zaghlol H, et al. 2012. Association of IL28B SNP with progression of Egyptian HCV genotype 4 patients to end stage liver disease. Hepat. Mon. 12:271–227.
   PubMed Web of Science ®Google Scholar
• El-Garawani I. 2015. Ameliorative effect of Cymbopogon citratus extract on cisplatin-induced genotoxicity in human leukocytes. J. Biosci. Appl. Res. 1(6):304–10.
   Google Scholar
• El-Nabi S, Sayed S, Abd-Elhafez M, Elfiky M, Abdel Moneim A, El-Garawani I. 2019. Arg753Gln polymorphisms in the toll-like receptor 2 gene are associated with cytomegalovirus infection in Egyptian bone marrow recipients. Endocr.Med. Immune Disord. Drug Targets. 19:1–6.
   PubMedGoogle Scholar
• Esmail MA, Hassuna NA, Amr KS, Ghazawy ER, Abdel-Hamid M. 2016. Polymorphisms at IL28B gene as predictors of viral relapse in genotype 4 Egyptian hepatitis C patients. J. Med. Virol. 88(3):481–86. doi:10.1002/jmv.24354. Epub 2015 Aug 26.
   PubMed Web of Science ®Google Scholar
• Estes C, Abdel-Kareem M, Abdel-Razek W, Abdel-Sameea E, Abuzeid M, Gomaa A, Osman W, Razavi H, Zaghla H, Waked I. 2015. Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies. Aliment Pharmacol. Ther. 42:696–706. doi:10.1111/apt.13316. Epub 2015.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. 2018 Aug. EASL recommendations on treatment of hepatitis C. J. Hepatol. 69(2):461–511. doi:10.1016/j.jhep.2018.03.026.
   PubMed Web of Science ®Google Scholar
• Falleti E, Bitetto D, Fabris C, Cussigh A, Fornasiere E, Cmet S, Fumolo E, Bignulin S, Fontanini E, Cerutti A, et al. 2011. Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. J. Clin. Immunol. 31:891–99.
   PubMed Web of Science ®Google Scholar
• Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, et al. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 461(7262):399–401.
   PubMed Web of Science ®Google Scholar
• Hashem M, Zaghla H, Zakaria Z, Allam WR, Sameea EA, Mikhail NN, Sobhy M, Galal IF, Mokhtar Y, Hamdy S, et al. 2018. High spontaneous clearance of symptomatic iatrogenic acute hepatitis C genotype 4 infection. J. Med. Virol. 90(12):1841–47. doi:10.1002/jmv.25270. Epub 2018 Aug 13.
   PubMed Web of Science ®Google Scholar
• Hassab El-Nabi SE. 2004. Molecular studies on the relationship between apoptosis and DNA damage induced by dexamethasone and flummox in liver and spleen of rat and human leucocytess culture. J. Egypt. Ger. Soc. Zool. 45:175–202.
   Google Scholar
• Hilgenfeldt EG, Schlachterman A, Firpi RJ. 2015. Hepatitis C: treatment of difficult to treat patients. World J. Hepatol. 7(15):1953–63.
   PubMed Web of Science ®Google Scholar
• Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamachita T, Shirasaki T, Horimoto K, Tanaka Y, et al. 2010. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology. 139:499–509.
   PubMed Web of Science ®Google Scholar
• Islam MS, Miah MR, Roy PK, Rahman O, Siddique AB, Chowdhury J, Ahmed F, Rahman S, Khan MR. 2015. Genotypes of hepatitis C virus infection in Bangladeshi population. Mymensingh Med. J. 24:143–51.
   PubMedGoogle Scholar
• Kamal SM. 2017. Hepatitis C in developing countries: current and future challenges. Book Chapter 3. Academic Press. eBook ISBN: 9780128032343.
   Google Scholar
• Knapp S, Zakaria Z, Hashem M, Zaghla H, Khakoo A, Waked I, Thursz M, Abdelwahab SF. 2015. Influence of IFNL3.rs12979860 and IFNL4.ss469415590 polymorphism on clearance of hepatitis C virus infection among Egyptians. Hepatol. Int. 9(2):251–57.
   PubMed Web of Science ®Google Scholar
• Krekulova L, Rehak V, Riley LW. 2006. Structure and function of hepatitis C virus proteins: 15 years later. Folia. Microbiol. 51:665–80.
   PubMed Web of Science ®Google Scholar
• Lange CM, Zeuzem S. 2011. IL28B single nucleotide polymorphisms in the treatment of hepatitis C. J. Hepatol. 55(3):692–701.
   PubMed Web of Science ®Google Scholar
• Mohammad I, Priyanka G, Khushboo I. 2017. Molecular basis of hepatocellular carcinoma induced by hepatitis C virus infection. World J. Hepatol. 9:1305–14.
   PubMed Web of Science ®Google Scholar
• Omata M, Kanda T, Yu ML, Yokosuka O, Lim SG, Jafri W, Tatishi R, Hamid S, Chuang W, Wei L, et al. 2012. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol. Int. 6:409–35.
   PubMed Web of Science ®Google Scholar
• Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, McPhee F, Hughes EA, Noviello S, Swenson ES. 2016. Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology 63:1493–505.
   PubMed Web of Science ®Google Scholar
• Rallon NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, Shianna KV, Vispo E, Thompson A, McHutchison J, et al. 2010 May 15. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis. AIDS 24(8):F23–9.
   PubMed Web of Science ®Google Scholar
• Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, Bochud M, Battegay M, Bernasconi E, Borovicka J, et al., Swisset Hepatitis C Cohort Study, Swiss HIV Cohort Study. 2010. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138(4):1338–45.
   PubMed Web of Science ®Google Scholar
• Sedighimehr P, Irani S, Sakhaee F, Vaziri F, Aghasadeghi M, Sadat SM, Jamnani FR, Fateh A, Siadat SD. 2017. IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C. Arch. Virol. 162(1):181–89. doi:10.1007/s00705-016-3095-1. Epub 2016 Oct 6.
   PubMed Web of Science ®Google Scholar
• Shaker OG, Sadik NA. 2013. Polymorphisms in interleukin-10 and interleukin-28B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin-therapy. J. Gastroenterol. Hepatol. 27(12):1842–49.
   Web of Science ®Google Scholar
• Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, et al. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4(1):63–68.
   PubMed Web of Science ®Google Scholar
• Spach DH, Kim HN. 2017. Treatment of HCV genotype4, lesson 4. module 5; treatment of chronic hepatitis C infection. Last update: November 15th 2017. [accessed 2017 Oct 8]. https:/www.hepatitisc.uw.edu/go/treatment-infection/treatment-genotype-4/core-concept/all.
   Google Scholar
• Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, et al. 2009. IL28B is associated with response to chronic hepatitis C interferon alpha and ribavirin therapy. Nat. Genet. 41(10):1100–04.
   PubMed Web of Science ®Google Scholar
• Taheri S, Aygen B, Korkmaz K, Yıldız O, Zararsız G, Canatan H. 2015. Characterization of the Interleukin-28B gene rs12979860 C/T polymorphism in Turkish chronic hepatitis C patients and healthy individuals. Balkan Med. J. 32(2):147–55.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, et al. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41:1105–09.
   PubMed Web of Science ®Google Scholar
• Tharwat E, Gad GFM, Nazmy MH, Mohamed HI, Hamza N, Wahid A, Ibrahim ARN. 2019. Impact of IL-27p28 (rs153109) and TNF-α (rs1800629) genetic polymorphisms on the progression of HCV infection in Egyptian patients. Immunol. Invest. 48(3):255–67. doi:10.1080/08820139.2018.1510958. Epub 2018 Sep 11.
   PubMed Web of Science ®Google Scholar
• Tolmane I, Rozentale B, Keiss J, Ivancenko L, Subnikova N, Reinholde Z, Kozlovska I, Sumlaninova N, Laivacuma S, Simanis R. 2012. Interleukin 28 B gene polymorphism and association with chronic hepatitis C therapy results in Latvia. Hepat. Res. Treat. 324090:4.
   Google Scholar
• Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin K, Hong L, McKnize A, Patel K, Shinna K, et al. 2010. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology. 52:1888–96.
   PubMed Web of Science ®Google Scholar
• Wahid A, Hamzawy MA, Khalifa MMA, Gad GFM, Bekhit A, Abdelwahab SF. 2019. RNA protein kinase SNP at −226 C<T is a biomarker for the clearance of HCV among Egyptian patients. Immunol. Invest. 48(3):211–21. doi:10.1080/08820139.2018.1493496. Epub 2018 Aug 6.
   PubMed Web of Science ®Google Scholar
• Zeremski M, Dimova RB, Makeyeva J, Sipley J, Jacobson I, Rennert H, Talal AH. 2013. IL28B polymorphism, pretreatment CXCL10, and HCV RNA Levels predict treatment response in racially diverse HIV/HCV co-infected and HCV mono infected patients. JAIDS J. Acquired Immune Deficiency Syndromes. 63(1):9–16.
   PubMed Web of Science ®Google Scholar